Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.99
-1.45 (-1.26%)
Streaming Delayed Price
Updated: 9:49 AM EDT, Jun 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
99
100
Next >
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
↗
July 28, 2025
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
Via
Benzinga
Merck & Co's Earnings Outlook
↗
July 28, 2025
Via
Benzinga
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
↗
July 28, 2025
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.
Via
Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
↗
July 28, 2025
These big pharma stocks arguably aren't receiving the respect they deserve.
Via
The Motley Fool
Topics
Intellectual Property
What To Expect From Merck’s (MRK) Q2 Earnings
July 27, 2025
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
P/E Ratio Insights for Merck & Co
↗
July 24, 2025
Via
Benzinga
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
↗
July 21, 2025
Via
Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
↗
July 21, 2025
Via
Stocktwits
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
↗
July 26, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via
Benzinga
Topics
Artificial Intelligence
ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
↗
July 25, 2025
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via
Benzinga
Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential
↗
July 25, 2025
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.
Via
Chartmill
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
↗
July 23, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via
Investor's Business Daily
Merck & Co Unusual Options Activity For July 15
↗
July 15, 2025
Via
Benzinga
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
↗
July 15, 2025
Via
Stocktwits
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
↗
July 22, 2025
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.
Via
Investor's Business Daily
Merck Announces Fourth-Quarter 2025 Dividend
July 22, 2025
From
Merck & Co., Inc.
Via
Business Wire
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
↗
July 22, 2025
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.
Via
Chartmill
Does This Move Make Merck Stock a Buy?
↗
July 20, 2025
Via
The Motley Fool
Topics
Intellectual Property
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
↗
July 20, 2025
Via
The Motley Fool
Topics
Economy
Intellectual Property
Want Decades of Passive Income? Buy This ETF and Hold It Forever
↗
July 19, 2025
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
Stocks
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 19, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Got $200? 2 Dividend Stocks to Buy and Hold Forever
↗
July 19, 2025
Via
The Motley Fool
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
↗
July 17, 2025
Via
The Motley Fool
Topics
Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
↗
July 16, 2025
Via
Benzinga
1 Dow Jones Stock to Target This Week and 2 to Avoid
July 16, 2025
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors.
Via
StockStory
Topics
Stocks
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
↗
July 15, 2025
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Via
Benzinga
This House of Representative Just Bought Up To $30K In 3M Stock
↗
July 15, 2025
Via
Benzinga
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
↗
July 14, 2025
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.
Via
Benzinga
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
July 14, 2025
From
Merck & Co., Inc.
Via
Business Wire
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
↗
July 14, 2025
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
